Literature DB >> 27909316

Therapeutic Potential of Conjugated siRNAs for the Treatment of Major Depressive Disorder.

Francesc Artigas1,2,3, Analia Bortolozzi1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27909316      PMCID： PMC5143495          DOI： 10.1038/npp.2016.182

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  6 in total

1.  Acute 5-HT₁A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions.

Authors:  Albert Ferrés-Coy; Noemí Santana; Anna Castañé; Roser Cortés; María C Carmona; Miklos Toth; Andrés Montefeltro; Francesc Artigas; Analía Bortolozzi
Journal:  Psychopharmacology (Berl)       Date:  2012-07-21       Impact factor: 4.530

2.  Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects.

Authors:  A Bortolozzi; A Castañé; J Semakova; N Santana; G Alvarado; R Cortés; A Ferrés-Coy; G Fernández; M C Carmona; M Toth; J C Perales; A Montefeltro; F Artigas
Journal:  Mol Psychiatry       Date:  2011-08-02       Impact factor: 15.992

Review 3.  Environmental and pharmacological modulations of cellular plasticity: role in the pathophysiology and treatment of depression.

Authors:  Kristie T Ota; Ronald S Duman
Journal:  Neurobiol Dis       Date:  2012-06-09       Impact factor: 5.996

4.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

Review 5.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2015-06-07       Impact factor: 202.731

6.  Therapeutic antidepressant potential of a conjugated siRNA silencing the serotonin transporter after intranasal administration.

Authors:  A Ferrés-Coy; M Galofré; F Pilar-Cuéllar; R Vidal; V Paz; E Ruiz-Bronchal; L Campa; Á Pazos; J R Caso; J C Leza; G Alvarado; A Montefeltro; E M Valdizán; F Artigas; A Bortolozzi
Journal:  Mol Psychiatry       Date:  2015-06-23       Impact factor: 15.992
  6 in total
  2 in total

1.  Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.

Authors:  Diana Alarcón-Arís; Ariadna Recasens; Mireia Galofré; Iria Carballo-Carbajal; Nicolás Zacchi; Esther Ruiz-Bronchal; Rubén Pavia-Collado; Rosario Chica; Albert Ferrés-Coy; Marina Santos; Raquel Revilla; Andrés Montefeltro; Isabel Fariñas; Francesc Artigas; Miquel Vila; Analia Bortolozzi
Journal:  Mol Ther       Date:  2017-11-29       Impact factor: 11.454

2.  Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys.

Authors:  Diana Alarcón-Arís; Rubén Pavia-Collado; Lluis Miquel-Rio; Valentín Coppola-Segovia; Albert Ferrés-Coy; Esther Ruiz-Bronchal; Mireia Galofré; Verónica Paz; Leticia Campa; Raquel Revilla; Andrés Montefeltro; Jeffrey H Kordower; Miquel Vila; Francesc Artigas; Analia Bortolozzi
Journal:  EBioMedicine       Date:  2020-08-15       Impact factor: 8.143
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.